We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

MDL Isentris Platform Selected by LEO Pharma

MDL Isentris Platform Selected by LEO Pharma

MDL Isentris Platform Selected by LEO Pharma

MDL Isentris Platform Selected by LEO Pharma

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDL Isentris Platform Selected by LEO Pharma"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Elsevier MDL has announced that LEO Pharma has selected the complete MDL® Isentris® information management and integration platform for its R&D operations.

As the first open-standards-based, n-tier discovery informatics platform designed for life sciences researchers, Isentris is effectively integrating the data and workflow applications scientists use every day and promoting a self-service research environment to enhance decision making and improve R&D productivity.

"LEO Pharma is a global company committed to developing innovative and efficacious products and associated services," said Karsten Linneberg, head of section, R&D IT, department of spectroscopy 751, LEO Pharma.

"As such, we are continually seeking to improve the day-to-day efficiency and productivity of our R&D teams."

"By playing a central role in integrating data and workflow applications and fostering knowledge-driven decisions, Isentris will accelerate and streamline LEO Pharma's intensive R&D activities."

"The complete MDL Isentris platform offers research organizations a clear path to better decisions, shorter cycle times and a higher return on investment," said Lars Barfod, president & chief executive officer of Elsevier MDL.

"We are delighted that LEO Pharma has elected to migrate from MDL® ISIS to the full suite of next-generation MDL Isentris products."

"This is further confirmation that Isentris is being accepted as the integrated informatics platform of choice for life sciences R&D organizations."

The MDL Isentris platform includes the MDL® Base user interface, MDL® Draw chemical drawing and rendering software, MDL® Core Interface middle tier with Integrating Data Source and the MDL® Direct chemical data cartridges for molecules and reactions.